Andere talen Portage Biotech Inc.

Aandelen

PRTG

VGG7185A1286

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,2426 ^USD	-18,37%		-13,67%	-86,67%

15/04	Portage Biotech kondigt plannen aan om de evaluatie van strategische alternatieven uit te breiden	CI
12/04	Portage Biotech kondigt plannen aan om de evaluatie van strategische alternatieven uit te breiden	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused	15/04
Portage biotech announces plans to expand its evaluation of strategic alternatives	15/04
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	15/04
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives	12/04
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	12/04
Portage biotech completes monetization of intensity therapeutics shares	27/03
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03
Portage Biotech : Corporate Presentation - March 2024	07/03
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update	28/02
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	28/02
Portage Biotech to Pause Drug Development in PORT-2 iNKT Program, to Cut Workforce	04/01
Portage Biotech to Evaluate Range of Strategic Options	04/01
Portage Biotech Reports Business and Strategic Update	04/01
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	28/11
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update	28/11
Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's 38th annual meeting	07/11
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	06/11
Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting	06/11
Portage Biotech Inc. announced that it has received $5.3 million in funding	03-10-23
Portage biotech announces $6.0 million registered direct offering	02-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Portage Biotech Inc.

Aandelen

PRTG

VGG7185A1286

Andere talen

Filters